Proteína C reactiva, procalcitonina y proadrenomedulina en la evolución de neumonías hospitalizadas

Llorens, 2009, Epidemiologic study of community-acquired pneumonia treated at a tertiary-care hospital: Does Fine's pneumonia severity index influence decision-making in the emergency department?, Emergencias., 21, 247 Almirall, 2000, Epidemiology of community acquired pneumonia in adults: a population based study, Eur Respir J., 15, 757, 10.1034/j.1399-3003.2000.15d21.x Santos de Unamuno, 1998, Lugar de atención, etiología y tratamiento de las neumonías adquiridas en la comunidad de Palma de Mallorca, Med Clin (Barc)., 110, 290 Murrie, 1991, Epidemiología de las neumonías adquiridas en la comunidad en el área de Salud I de Navarra, Med Clin (Barc)., 97, 50 Suchyta, 2001, Effects of a practice guideline for community-acquired pneumonia in an outpatient setting, Am J Med., 110, 306, 10.1016/S0002-9343(00)00719-1 Fine, 1997, A prediction rule to identify low risk patients with community-acquired pneumonia, N Engl J Med., 336, 243, 10.1056/NEJM199701233360402 Lim, 2003, Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study, Thorax., 58, 377, 10.1136/thorax.58.5.377 España, 2006, Development and validation of a clinical prediction rule for severe community-acquired pneumonia, Am J Respir Crit Care Med., 174, 1249, 10.1164/rccm.200602-177OC Charles, 2008, SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia, Clin Infect Diseases., 47, 375, 10.1086/589754 Torres, 2010, Update in community-acquired and nosocomial pneumonia 2009, Am J Respir Crit Care Med., 181, 782, 10.1164/rccm.201001-0030UP Niederman, 2009, Making sense of scoring systems in community acquired pneumonia, Respirology., 14, 327, 10.1111/j.1440-1843.2009.01494.x Mira JP, Max A, Burgel PR. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Critical Care. 2008;12 Suppl 6:S5. Povoa, 2005, C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study, Eur Respir J., 25, 804, 10.1183/09031936.05.00071704 Almirall, 2004, Contribution of C-reactive protein to the diagnosis and assessment of severity of community acquired pneumonia., Chest, 125, 1335, 10.1378/chest.125.4.1335 Hohenthal, 2009, Utility of C-reactive protein in assessing the disease severity and complications of community acquired pneumonia, Clin Microbiol Infect., 15, 1026, 10.1111/j.1469-0691.2009.02856.x Seligman, 2006, Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia, Crit Care., 10, R125, 10.1186/cc5036 Kofoed, 2007, Crit Care., 11, R38, 10.1186/cc5723 Joyce, 1990, Calcitonin gene-related peptide levels are elevated in patients with sepsis, Surgery., 108, 1097 Kruger, 2008, Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes, Eur Respir J., 31, 349, 10.1183/09031936.00054507 Huang, 2008, Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired Pneumonia, Ann Emerg Med., 52, 48, 10.1016/j.annemergmed.2008.01.003 Masía, 2005, Usefulness of Procalcitonin Levels in Community-Acquired Pneumonia According to the Patients Outcome Research Team Pneumonia Severity Index, Chest., 128, 2223, 10.1378/chest.128.4.2223 Christ-Crain, 2006, Procalcitonin-Guidance of Antibiotic Therapy in Communiy-Acquired Pneumonia – A Randomized Trial, Am J Respir Crit Care Med., 174, 84, 10.1164/rccm.200512-1922OC Huang, 2009, Midregional Proadrenomedullin as a Prognostic Tool in Community-Acquired Pneumonia, Chest., 136, 823, 10.1378/chest.08-1981 Christ-Crain, 2006, Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia, Crit Care., 10, R96, 10.1186/cc4443 Christ-Crain, 2010, Clinical review: the role of biomarkers in the diagnosis and management of community acquired pneumonia, Critical Care., 14, 203, 10.1186/cc8155 Summah, 2009, Biomarkers: a definite plus in pneumonia, Mediators of Inflammation., 1, 10.1155/2009/675753 Schuetz, 2010, Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections, Critical Care., 14, R106, 10.1186/cc9055 Chalmers, 2008, C-reactive protein is an independent predictor of severity in community-acquired pneumonia, Am J Med., 121, 219, 10.1016/j.amjmed.2007.10.033 Cabezas, 2010, Factores que modifican la producción de proteína C-reactiva en pacientes con neumonía adquirida en la comunidad, Arch Bronconeumol., 46, 47, 10.1016/j.arbres.2009.05.006